BIMINI Biotech closed a €3M seed investment round led by Torrey Pines Investment to support preclinical development of modulators targeting WASp, a key protein in immune cells.
WASp, primarily found in immune cells, is crucial for immune function and cell movement. Targeting it represents a novel approach to combatting hematological cancers.
BIMINI's technology demonstrates promising anti-cancer effects in lymphoma and leukaemia models, aiming to improve treatment outcomes for patients with limited options due to traditional therapies.
The funding will enhance preclinical development of WASp modulators and employ advanced platforms for drug discovery, showcasing BIMINI's innovative approach in the biotech field.
Collection
[
|
...
]